[go: up one dir, main page]

MX2013012088A - Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. - Google Patents

Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.

Info

Publication number
MX2013012088A
MX2013012088A MX2013012088A MX2013012088A MX2013012088A MX 2013012088 A MX2013012088 A MX 2013012088A MX 2013012088 A MX2013012088 A MX 2013012088A MX 2013012088 A MX2013012088 A MX 2013012088A MX 2013012088 A MX2013012088 A MX 2013012088A
Authority
MX
Mexico
Prior art keywords
molecules
antibodies
join
relates
bind
Prior art date
Application number
MX2013012088A
Other languages
English (en)
Other versions
MX338353B (es
Inventor
Solomon Langermann
Linda Liu
Shannon Marshall
Sheng Yao
Original Assignee
Amplimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplimmune Inc filed Critical Amplimmune Inc
Publication of MX2013012088A publication Critical patent/MX2013012088A/es
Publication of MX338353B publication Critical patent/MX338353B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos y sus fragmentos de unión a antígeno y a otras moléculas que son capaces de unirse inmunoespecíficamente a B7-H1 o PD-1. En algunas modalidades, dichas moléculas adicionalmente pueden modular la habilidad de B7-H1 o B7-DC para unirse a PD-1 o son capaces de afectar la actividad de señalización de la B7-H1 o PD-1. La invención además se refiere a los usos de dichas moléculas en el diagnóstico y tratamiento de cáncer y otras enfermedades.
MX2013012088A 2011-04-20 2012-04-19 Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. MX338353B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477414P 2011-04-20 2011-04-20
PCT/US2012/034223 WO2012145493A1 (en) 2011-04-20 2012-04-19 Antibodies and other molecules that bind b7-h1 and pd-1

Publications (2)

Publication Number Publication Date
MX2013012088A true MX2013012088A (es) 2014-04-30
MX338353B MX338353B (es) 2016-04-13

Family

ID=47041916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012088A MX338353B (es) 2011-04-20 2012-04-19 Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.

Country Status (21)

Country Link
US (2) US9205148B2 (es)
EP (2) EP3403672A1 (es)
JP (2) JP6072771B2 (es)
KR (1) KR101970025B1 (es)
CN (1) CN103608040B (es)
AU (1) AU2012245477C1 (es)
CA (1) CA2833636A1 (es)
CY (1) CY1120626T1 (es)
DK (1) DK2699264T3 (es)
ES (1) ES2669310T3 (es)
HR (1) HRP20180893T1 (es)
HU (1) HUE037651T2 (es)
LT (1) LT2699264T (es)
MX (1) MX338353B (es)
PL (1) PL2699264T3 (es)
PT (1) PT2699264T (es)
RS (1) RS57324B1 (es)
RU (1) RU2625034C2 (es)
SI (1) SI2699264T1 (es)
SM (1) SMT201800294T1 (es)
WO (1) WO2012145493A1 (es)

Families Citing this family (826)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
CN104955475A (zh) * 2012-12-19 2015-09-30 艾普利穆恩公司 抗人b7-h4抗体及其用途
JP6359031B2 (ja) * 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
DK2964638T3 (en) 2013-03-06 2017-10-30 Astrazeneca Ab QUINAZOLIN INHIBITORS TO ACTIVATE MUTANEOUS FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR
KR20230070054A (ko) * 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
WO2014194293A1 (en) * 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
KR102457731B1 (ko) 2013-08-08 2022-10-21 싸이튠 파마 병용 약학 조성물
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
IL296026B2 (en) * 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
WO2015048312A1 (en) * 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
DK3081576T3 (da) 2013-12-12 2019-10-21 Shanghai hengrui pharmaceutical co ltd Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
LT3087071T (lt) 2013-12-24 2018-11-12 Bristol-Myers Squibb Company Tricikliniai junginiai kaip priešvėžiniai agentai
EP3092254A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating her2 positive tumors
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106255510A (zh) 2014-03-05 2016-12-21 百时美施贵宝公司 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
WO2015176033A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CN105330740B (zh) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
RU2722212C9 (ru) 2014-08-05 2020-07-23 СиБи ТЕРЕПЬЮТИКС, ИНК. Анти-pd-l1 антитела
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
ES2825576T3 (es) 2014-09-16 2021-05-17 Innate Pharma Neutralización de rutas inhibidoras en linfocitos
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
CA2957813C (en) 2014-10-10 2025-07-08 Innate Pharma CD73 BLOCKAGE
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
JP6821560B2 (ja) 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
MY184103A (en) 2014-10-23 2021-03-18 Regeneron Pharma Novel cho integration sites and uses thereof
DK3209778T3 (da) 2014-10-24 2019-05-27 Astrazeneca Kombination
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
RS61602B1 (sr) 2014-10-29 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
BR112017008575B1 (pt) 2014-10-29 2021-07-13 Bicyclerd Limited Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
WO2016140884A1 (en) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
US10399933B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
RS60753B1 (sr) 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
KR20250107941A (ko) 2015-04-28 2025-07-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
PT3303396T (pt) 2015-05-29 2023-01-30 Bristol Myers Squibb Co Anticorpos contra ox40 e utilizações dos mesmos
WO2016196218A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
EP3322731B1 (en) 2015-07-14 2021-01-13 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
EP3328861A1 (en) 2015-07-28 2018-06-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CR20200423A (es) 2015-07-30 2021-01-20 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
EP3331901A1 (en) 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Novel fusion polypeptide specific for lag-3 and pd-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN106432494B9 (zh) * 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
PT3334763T (pt) 2015-08-11 2024-10-28 Wuxi Biologics Ireland Ltd Novos anticorpos anti-pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
WO2017035118A1 (en) 2015-08-25 2017-03-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
HK1251158A1 (zh) * 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
JP2018529351A (ja) 2015-09-30 2018-10-11 ヤンセン バイオテツク，インコーポレーテツド ヒトｃｄ４０に特異的に結合するアンタゴニスト抗体及び使用方法
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
DK3356404T3 (da) * 2015-10-02 2021-10-25 Hoffmann La Roche Anti-pd1-antistoffer og fremgangsmåder til anvendelse
HK1251475A1 (zh) 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
US20180318365A1 (en) 2015-10-19 2018-11-08 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US10815304B2 (en) * 2015-11-17 2020-10-27 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
TWI821748B (zh) 2015-11-18 2023-11-11 美商必治妥施貴寶公司 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
TWI791422B (zh) 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
MY197345A (en) 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
EP3390406A1 (en) 2015-12-15 2018-10-24 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
EP3403091B1 (en) 2016-01-11 2021-12-22 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
CN116327916A (zh) 2016-01-21 2023-06-27 依奈特制药公司 对淋巴细胞中抑制途径的中和
EP3405497A2 (en) 2016-01-22 2018-11-28 Mabquest SA Immunological reagents
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
DK3411065T3 (da) 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
SG11201806861SA (en) 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US11078274B2 (en) 2016-03-08 2021-08-03 Innate Pharma Siglec neutralizing antibodies
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
EP4302782A3 (en) 2016-03-15 2024-03-27 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017167921A1 (en) 2016-03-30 2017-10-05 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019519485A (ja) 2016-05-04 2019-07-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
KR20190004742A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
US10323004B2 (en) 2016-05-04 2019-06-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
EP4248990A3 (en) 2016-06-02 2024-01-03 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
WO2017210473A1 (en) 2016-06-02 2017-12-07 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
CN109476754A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 抗-pd-1抗体在治疗结肠直肠癌患者中的用途
EP4386005A3 (en) 2016-06-03 2024-09-04 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
CN109476753A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗肿瘤的方法的抗-pd-1抗体
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3471754A1 (en) * 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
EP3497128A2 (en) 2016-08-09 2019-06-19 Kymab Limited Anti-icos antibodies
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
MA45999A (fr) 2016-08-22 2019-06-26 Arbutus Biopharma Corp Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018039518A1 (en) 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
US11390675B2 (en) 2016-09-21 2022-07-19 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
JP7424727B2 (ja) 2016-09-29 2024-01-30 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド ヘテロダイマー免疫グロブリン構造体及びその製造方法
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
KR102634093B1 (ko) 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
BR112019008223A2 (pt) 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EA201990894A9 (ru) 2016-11-18 2019-11-27 Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018101448A1 (en) 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
PT3551660T (pt) 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
EP3559045A4 (en) * 2016-12-23 2020-08-19 REMD Biotherapeutics, Inc. IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MA47265A (fr) 2017-01-13 2019-11-20 Agenus Inc Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
CA3050009A1 (en) * 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
US20200237874A1 (en) 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
EP3570844B1 (en) 2017-01-20 2023-09-06 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2018134681A1 (en) 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
JP7161481B2 (ja) 2017-02-10 2022-10-26 ノバルティス アーゲー １－（４－アミノ－５－ブロモ－６－（１ｈ－ピラゾール－１－イル）ピリミジン－２－イル）－１ｈ－ピラゾール－４－オール及びがんの治療におけるその使用
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
UY37621A (es) 2017-02-28 2018-09-28 Sanofi Sa Arn terapéutico que codifica citoquinas
EP3596124A1 (en) 2017-03-16 2020-01-22 Innate Pharma Compositions and methods for treating cancer
SG10202110594UA (en) 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
EP3601353A1 (en) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
SG10201913676QA (en) * 2017-04-01 2020-03-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
US12460208B2 (en) 2017-04-18 2025-11-04 Parr Biotechnology Co., Ltd. Immunomodulatory polynucleotides and uses thereof
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
EP3612030B1 (en) 2017-04-21 2025-12-24 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
EP3615070A1 (en) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP4275698A3 (en) 2017-05-01 2024-05-15 Agenus Inc. Anti-tigit antibodies and methods of use thereof
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
EP3634417B1 (en) 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2018222711A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
CN110678483B (zh) 2017-06-01 2023-09-22 百时美施贵宝公司 用抗pd-1抗体治疗肿瘤的方法
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2018231827A1 (en) * 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2018287519B2 (en) 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
KR20220031738A (ko) 2017-06-27 2022-03-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
JP2020525483A (ja) 2017-06-27 2020-08-27 ノバルティス アーゲー 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
EP3421494A1 (en) 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
CN111093651B (zh) 2017-06-30 2023-06-06 百时美施贵宝公司 Ido抑制剂的无定形和结晶形式
CA3068933A1 (en) 2017-07-06 2019-01-10 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
US11623954B2 (en) 2017-07-10 2023-04-11 Innate Pharma Siglec-9-neutralizing antibodies
KR102698385B1 (ko) 2017-07-14 2024-08-22 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
CA3070519A1 (en) 2017-07-21 2019-01-24 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
JP7186764B2 (ja) 2017-07-28 2022-12-09 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
CN111148996A (zh) 2017-07-28 2020-05-12 百时美施贵宝公司 用于检查点抑制剂的预测性外周血生物标志物
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
JP2020530003A (ja) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド 抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
EP3668496A4 (en) 2017-08-17 2021-07-14 Ikena Oncology, Inc. AHR INHIBITORS AND THEIR USES
CN119552248A (zh) 2017-08-25 2025-03-04 戊瑞治疗有限公司 B7-h4抗体及其使用方法
MX2020001980A (es) 2017-08-28 2020-03-24 Bristol Myers Squibb Co Antagonistas de celulas t con dominios de inmunoglobulina y mucina 3 (tim-3) para el tratamiento y diagnostico de canceres.
CN111032672B (zh) 2017-08-31 2024-09-13 百时美施贵宝公司 作为抗癌剂的环二核苷酸
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
KR20200052327A (ko) 2017-09-04 2020-05-14 아게누스 인코포레이티드 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
EP3691643A4 (en) 2017-09-29 2021-06-16 Bristol-Myers Squibb Company COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3694867B1 (en) 2017-10-10 2025-12-24 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
AU2018357221B2 (en) 2017-10-27 2025-08-28 Pfizer Inc. Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019090002A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
AU2018360790A1 (en) 2017-11-06 2020-06-11 Bristol-Myers Squibb Company Methods of treating a tumor
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019099977A2 (en) 2017-11-20 2019-05-23 Ariagen, Inc. Indole compounds and their use
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
US11324774B2 (en) 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
SG11202005323SA (en) 2018-01-12 2020-07-29 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2021511372A (ja) 2018-01-16 2021-05-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｍ３に対する抗体で癌を処置する方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EA202091751A1 (ru) 2018-01-22 2020-11-06 Бристол-Маерс Сквибб Компани Композиции и способы лечения рака
US20210038559A1 (en) 2018-01-22 2021-02-11 Thomas Richard Gadek Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CN112135614A (zh) 2018-01-24 2020-12-25 大连万春布林医药有限公司 通过施用普那布林减少血小板减少症的组合物和方法
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3746480A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Bispecific antibodies comprising an antigen-binding site binding to lag3
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019157124A1 (en) 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
AU2019222747B2 (en) 2018-02-16 2024-09-05 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP3759142A1 (en) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
KR20200130362A (ko) 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
JP2021519771A (ja) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
CN112292399A (zh) 2018-04-04 2021-01-29 百时美施贵宝公司 抗cd27抗体及其用途
EP3773714A1 (en) 2018-04-12 2021-02-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
PE20210160A1 (es) 2018-04-25 2021-01-26 Innate Tumor Immunity Inc Moduladores de nlrp3
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
EP3788147A1 (en) 2018-05-04 2021-03-10 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
CN115991787A (zh) * 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
IL319456A (en) 2018-06-20 2025-05-01 Incyte Holdings Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
BR112020026384A2 (pt) 2018-06-23 2021-03-30 Genentech, Inc. Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
FI3814348T3 (fi) 2018-06-27 2023-09-22 Bristol Myers Squibb Co Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
LT3814347T (lt) 2018-06-27 2023-07-10 Bristol-Myers Squibb Company Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
PE20211604A1 (es) 2018-07-09 2021-08-23 Five Prime Therapeutics Inc Anticuerpos de union a ilt4
LT3820573T (lt) 2018-07-10 2023-11-10 Novartis Ag 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN113015523B (zh) 2018-07-18 2024-07-16 艾库斯生物科学有限公司 偶氮嘧啶化合物的固体形式
CA3104147A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
AU2019306628B2 (en) 2018-07-20 2024-11-14 Surface Oncology, LLC Anti-CD112R compositions and methods
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CA3107660A1 (en) 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
ES2974964T3 (es) 2018-08-16 2024-07-02 Innate Tumor Immunity Inc Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
JP2021534180A (ja) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
KR102768379B1 (ko) 2018-08-16 2025-02-13 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
WO2020041655A1 (en) 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
CA3106881A1 (en) 2018-08-27 2020-03-05 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
EP3853247A2 (en) 2018-09-19 2021-07-28 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022504905A (ja) 2018-10-16 2022-01-13 ノバルティス アーゲー 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
HRP20241325T1 (hr) 2018-10-19 2024-12-20 Bristol-Myers Squibb Company Kombinirana terapija za melanom
CN112912403A (zh) 2018-10-23 2021-06-04 百时美施贵宝公司 治疗肿瘤的方法
KR20210084546A (ko) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP2022512973A (ja) 2018-11-09 2022-02-07 ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー 腫瘍微小環境の組成を測定するための方法及び組成物
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
UY38476A (es) 2018-11-16 2020-06-30 Arcus Biosciences Inc Inhibidores de arg1 y/o arg2
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
TW202038943A (zh) 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP3899951A1 (en) 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
CN111423510B (zh) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
TW202515617A (zh) 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
WO2020150114A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
KR102903509B1 (ko) 2019-01-14 2025-12-22 인네이트 튜머 이뮤니티, 인코포레이티드 암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린
CN113286787A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
CN113286786A (zh) 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
EP3911302B1 (en) 2019-01-17 2025-09-10 Georgia Tech Research Corporation Drug delivery systems containing oxidized cholesterols
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
BR112021015487A2 (pt) 2019-02-12 2021-10-05 Novartis Ag Combinação farmacêutica que compreende tno155 e um inibidor de pd-1
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
CN113544271B (zh) 2019-02-27 2025-07-11 Ionis制药公司 Malat1表达的调节剂
EP3937964A4 (en) 2019-03-12 2022-11-16 Arcus Biosciences, Inc. TREATMENT OF ONCOGENE-DRIVEN CANCERS
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220152179A1 (en) 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN113891748A (zh) 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
AU2020258394A1 (en) 2019-04-15 2021-10-28 Ariagen, Inc. Chiral indole compounds and their use
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2022530674A (ja) 2019-05-03 2022-06-30 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体を用いたがんの処置方法
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
CN113825527A (zh) 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
KR20220041079A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
WO2020255011A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025140A1 (ja) * 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
AU2020347274A1 (en) 2019-09-13 2022-03-31 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
US20220402901A1 (en) 2019-09-17 2022-12-22 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
CA3150906A1 (en) 2019-09-17 2021-03-25 Renato T. Skerlj Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
KR20220100858A (ko) 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다졸 카르복사미드, 및 질병의 치료에서의 이의 용도
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
MX2022003204A (es) 2019-09-19 2022-04-18 Bristol Myers Squibb Co Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
CA3153777A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
EP4034154A1 (en) 2019-09-25 2022-08-03 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
BR112022005655A2 (pt) 2019-09-25 2022-09-06 Bristol Myers Squibb Co Biomarcador compósito para terapia para câncer
WO2021064567A1 (en) 2019-09-30 2021-04-08 Astrazeneca Ab Combination treatment for cancer
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
WO2021077250A1 (zh) * 2019-10-21 2021-04-29 康源博创生物科技(北京)有限公司 一种抗pd-l1的抗体及其制药用途
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
MX2022005376A (es) 2019-11-04 2022-05-19 Alector Llc Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
US11548870B2 (en) 2019-11-19 2023-01-10 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
CA3160307A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
US12527783B2 (en) 2019-11-26 2026-01-20 Bristol-Myers Squibb Company Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
CA3159317A1 (en) 2019-11-26 2021-06-03 Alfredo C. Castro Polymorphic carbazole derivatives and uses thereof
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
BR112022011268A2 (pt) 2019-12-09 2022-09-06 Seagen Inc Terapia de combinação com antagonista de liv1-adc e pd1
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
AU2020407130A1 (en) 2019-12-19 2022-06-16 Bristol-Myers Squibb Company Combinations of DGK inhibitors and checkpoint antagonists
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
AU2020412698A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as T cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
EP4081308A4 (en) 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. SMARCA DEGRADERS AND USES THEREOF
WO2021133748A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
EP4081516B1 (en) 2019-12-23 2025-07-30 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
CN114846015B (zh) 2019-12-23 2024-07-30 百时美施贵宝公司 用作t细胞激活剂的经取代的杂芳基化合物
US20230045791A1 (en) 2020-01-06 2023-02-16 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
AU2021205143A1 (en) 2020-01-07 2022-07-28 Hifibio, Inc. Anti-Galectin-9 antibody and uses thereof
JP7573622B2 (ja) 2020-01-10 2024-10-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
US11534441B2 (en) 2020-01-15 2022-12-27 Blueprint Medicines Corporation MAP4K1 inhibitors
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
JP2023511439A (ja) 2020-01-28 2023-03-17 ジェネンテック， インコーポレイテッド がんの治療のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質
WO2021152005A1 (en) 2020-01-28 2021-08-05 Universite De Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
MX2022009270A (es) 2020-01-30 2022-10-27 Ona Therapeutics S L Un inhibidor de cd36 para usarse en una terapia combinada para el tratamiento de cáncer y la metástasis del cáncer.
TW202142257A (zh) 2020-01-31 2021-11-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗誘導新抗原決定基特異性ｔ細胞之方法
KR20220139915A (ko) 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
EP4106788A1 (en) 2020-02-18 2022-12-28 Alector LLC Pilra antibodies and methods of use thereof
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
CA3170456A1 (en) 2020-03-06 2021-09-10 Ellen Filvaroff Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
BR112022016720A2 (pt) 2020-03-06 2022-11-16 Ona Therapeutics S L Anticorpos anti-cd36 e seu uso para tratamento de câncer
KR20220151189A (ko) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 증진된 효능제 활성을 갖는 cd40에 대한 항체
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
JP7474861B2 (ja) 2020-03-19 2024-04-25 アーカス バイオサイエンシーズ，インコーポレーテッド Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物
IL296673A (en) 2020-03-23 2022-11-01 Bristol Myers Squibb Co Anti-ccr8 antibodies for treating cancer
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023519673A (ja) 2020-03-31 2023-05-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 置換ピリミジンおよび使用方法
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
TW202200137A (zh) 2020-04-21 2022-01-01 瑞士商諾華公司 用於治療由csf-1r調節的疾病之給藥方案
SE2050559A1 (en) * 2020-05-13 2021-11-14 Khs Biomedinvent Ab PD-1 as a predictive marker for therapy in cancer
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP7776448B2 (ja) 2020-06-02 2025-11-26 アーカス バイオサイエンシズ インコーポレイティド Ｔｉｇｉｔに対する抗体
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202214623A (zh) 2020-06-10 2022-04-16 美商施萬生物製藥研發 Ip有限責任公司 結晶型alk5抑制劑及其用途
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CA3187255A1 (en) 2020-07-30 2022-02-03 Duncan Walker Methods of treating mutant lymphomas
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3188996A1 (en) 2020-08-10 2022-02-17 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
CA3168743A1 (en) 2020-08-26 2022-03-03 Matthew G. Fury Methods of treating cancer by administering a pd-1 inhibitor
KR20230058442A (ko) 2020-08-28 2023-05-03 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 lag-3 길항제 요법
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
US20230381309A1 (en) * 2020-10-13 2023-11-30 Immunovaccine Technologies Inc. Methods of treating diffuse large b-cell lymphoma
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer
MX2023004847A (es) 2020-10-28 2023-07-11 Ikena Oncology Inc Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina.
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
US12351643B2 (en) 2020-11-04 2025-07-08 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US12492261B2 (en) 2020-11-04 2025-12-09 Genentech, Inc. Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies
TWI838660B (zh) 2020-11-04 2024-04-11 美商建南德克公司 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
MX2023005530A (es) 2020-11-13 2023-05-25 Genentech Inc Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
JP2023551906A (ja) 2020-12-02 2023-12-13 ジェネンテック， インコーポレイテッド ネオアジュバントおよびアジュバント尿路上皮癌腫療法のための方法および組成物
AU2021392040A1 (en) 2020-12-02 2023-06-29 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
AU2021396381A1 (en) 2020-12-11 2023-07-06 The University Of North Carolina At Chapel Hill Compositions and methods comprising sfrp2 antagonists
CA3202330A1 (en) 2020-12-16 2022-06-23 Anthony Casarez Compounds useful as t cell activators
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
JP2024503379A (ja) 2021-01-08 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗フコシルｇｍ１抗体を使用した組み合わせ療法
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US12397055B2 (en) 2021-01-22 2025-08-26 Mendus B.V. Methods of tumor vaccination
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
MX2023009060A (es) 2021-02-02 2023-09-29 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
EP4291558A1 (en) 2021-02-12 2023-12-20 F. Hoffmann-La Roche AG Bicyclic tetrahydroazepine derivatives for the treatment of cancer
JP2024506909A (ja) 2021-02-12 2024-02-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CA3207380A1 (en) 2021-02-15 2022-08-18 Haojing RONG Irak4 degraders and uses thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
JP2024510989A (ja) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ ワクチン接種方法及びｃｄ４７遮断薬の使用
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
KR20230159590A (ko) 2021-03-23 2023-11-21 리제너론 파아마슈티컬스, 인크. Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
EP4313127A1 (en) 2021-03-29 2024-02-07 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3211727A1 (en) 2021-03-31 2022-10-06 Merus N.V. Novel pd-1 binding domains
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
JP2024515545A (ja) 2021-04-05 2024-04-10 ブリストル－マイヤーズ スクイブ カンパニー がん治療のためのピリジニル置換オキソイソインドリン化合物
PE20231941A1 (es) 2021-04-06 2023-12-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
IL307673A (en) 2021-04-16 2023-12-01 Ikena Oncology Inc MEK inhibitors and their use
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
IL309310A (en) 2021-06-18 2024-02-01 Genzyme Corp Antibody formulations against TGF-beta and their use
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202321237A (zh) 2021-07-14 2023-06-01 美商纜圖藥品公司 Ｍａｐ４ｋ１抑制劑
WO2023288264A1 (en) 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
EP4377351A1 (en) 2021-07-28 2024-06-05 F. Hoffmann-La Roche AG Methods and compositions for treating cancer
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
IL309934A (en) 2021-07-30 2024-03-01 Ona Therapeutics S L Anti-cd36 antibodies and their use to treat cancer
US20250215103A1 (en) 2021-08-03 2025-07-03 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use
EP4380596A1 (en) 2021-08-04 2024-06-12 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
EP4413040A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
AU2022377637A1 (en) 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
IL309227A (en) 2021-10-29 2024-02-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hematological cancer
WO2023076556A1 (en) 2021-10-29 2023-05-04 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023084445A1 (en) 2021-11-12 2023-05-19 Novartis Ag Combination therapy for treating lung cancer
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
JP2024541508A (ja) 2021-11-24 2024-11-08 ジェネンテック， インコーポレイテッド 治療用インダゾール化合物およびがんの治療における使用方法
CN118660964A (zh) 2021-12-16 2024-09-17 瓦莱里奥治疗公司 新型缀合核酸分子及其用途
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US20250215076A1 (en) 2022-01-26 2025-07-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
CN118984837A (zh) 2022-01-28 2024-11-19 乔治穆内公司 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4472963A1 (en) 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins
MX2024010310A (es) 2022-02-25 2024-08-28 Bristol Myers Squibb Co Terapia de combinacion para carcinoma colorrectal.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4493189A1 (en) 2022-03-14 2025-01-22 Laekna Limited Combination treatment for cancer
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CA3246312A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
CN119731651A (zh) 2022-04-08 2025-03-28 百时美施贵宝公司 三级淋巴结构的机器学习标识、分类和量化
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
KR20250006959A (ko) 2022-05-02 2025-01-13 아르커스 바이오사이언시즈 인코포레이티드 항-tigit 항체 및 이의 용도
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
JP2025517650A (ja) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2023220703A1 (en) 2022-05-12 2023-11-16 Genentech, Inc. Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
JP2025518785A (ja) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
CA3257760A1 (en) 2022-06-07 2023-12-14 Genentech, Inc. PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
JP2025523403A (ja) 2022-06-08 2025-07-23 タイダル・セラビューティクス・インコーポレイテッド イオン化可能なカチオン性脂質及び脂質ナノ粒子、並びにその合成方法及び使用
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558524A1 (en) 2022-07-19 2025-05-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
CN119923267A (zh) 2022-07-27 2025-05-02 阿斯利康(瑞典)有限公司 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合
EP4565568A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
AU2023317742A1 (en) 2022-08-02 2025-03-20 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
CN119654312A (zh) 2022-08-08 2025-03-18 百时美施贵宝公司 用作t细胞活化剂的取代的四唑基化合物
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
TW202417439A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫噻吖呯衍生物
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
EP4568958A1 (en) 2022-08-11 2025-06-18 F. Hoffmann-La Roche AG Bicyclic tetrahydrothiazepine derivatives
JP2025527578A (ja) 2022-08-18 2025-08-22 パルマトリックス オペレーティング カンパニー，インコーポレイテッド 吸入用血管新生阻害剤を用いてがんを治療する方法
EP4581366A1 (en) 2022-09-01 2025-07-09 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
AU2023341373A1 (en) 2022-09-14 2025-03-06 Arcus Biosciences, Inc. Dispersions of etrumadenant
CN120379691A (zh) 2022-09-30 2025-07-25 爱兰蒂斯疗法股份公司 耐药性肝细胞癌的治疗
WO2024073111A2 (en) * 2022-09-30 2024-04-04 Adicet Therapeutics, Inc. Affinity binding entities directed to b7h6 and methods of use thereof
EP4599088A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
JP7730432B2 (ja) 2022-10-19 2025-08-27 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
KR20250080902A (ko) 2022-10-20 2025-06-05 아르커스 바이오사이언시즈 인코포레이티드 Cd73 화합물의 동결건조된 제형
EP4605422A2 (en) 2022-10-20 2025-08-27 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
EP4608390A1 (en) 2022-10-24 2025-09-03 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
CN120112796A (zh) 2022-10-25 2025-06-06 基因泰克公司 多发性骨髓瘤的治疗和诊断方法
WO2024102635A1 (en) 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment
TW202430148A (zh) 2022-11-22 2024-08-01 美商皮克醫療公司 ｅＩＦ４Ｅ抑制劑及其用途
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN120390652A (zh) 2022-12-01 2025-07-29 免疫医疗有限公司 用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
KR20250122520A (ko) 2022-12-20 2025-08-13 제넨테크, 인크. Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN120418281A (zh) * 2022-12-29 2025-08-01 财团法人生物技术开发中心 靶向PD-L1和中和Gas6之融合蛋白及其用途
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
EP4649173A1 (en) 2023-01-13 2025-11-19 Akrivia Biomedics Limited Method of profiling diseases
KR20250140097A (ko) 2023-01-30 2025-09-24 키맵 리미티드 항체
AU2024225483A1 (en) 2023-02-23 2025-08-28 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
CN121127264A (zh) 2023-03-13 2025-12-12 瑞泽恩制药公司 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
TW202500139A (zh) 2023-05-08 2025-01-01 美商必治妥美雅史谷比公司 經取代之苯基㗁唑酮化合物
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
TW202509014A (zh) 2023-05-10 2025-03-01 美商纜圖藥品公司 ＧＳＫ３α抑制劑及其使用方法
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
AU2024281414A1 (en) 2023-06-02 2025-12-11 Arcus Biosciences, Inc. Biomarkers for predicting cancer treatment efficacy
AU2024285766A1 (en) 2023-06-07 2026-01-08 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
IL321489A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc IRAQ joints and their uses
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025038857A1 (en) 2023-08-16 2025-02-20 Arcus Biosciences, Inc. TETRALINS TARGETING MUTANT HIF-2α
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
WO2025051895A1 (en) 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
JP7808733B2 (ja) 2023-09-13 2026-01-29 ブリストル－マイヤーズ スクイブ カンパニー 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
US20250114468A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
US20250230173A1 (en) 2023-12-20 2025-07-17 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
TW202539700A (zh) 2024-01-16 2025-10-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
US20260022170A1 (en) 2024-05-10 2026-01-22 Adaptam Therapeutics S.L Anti-siglec-9 antibodies and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025254987A1 (en) 2024-06-03 2025-12-11 Alector Llc Siglec-9 ecd fusion molecule variants and methods of use thereof
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598520A (en) 1898-02-08 Marker s record for laundrymen
US529054A (en) 1894-11-13 Alfred zempliner
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
US6890487B1 (en) 1999-09-30 2005-05-10 Science & Technology Corporation ©UNM Flow cytometry for high throughput screening
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US7262838B2 (en) 2001-06-29 2007-08-28 Honeywell International Inc. Optical detection system for flow cytometry
US6784981B1 (en) 2000-06-02 2004-08-31 Idexx Laboratories, Inc. Flow cytometry-based hematology system
US6794152B2 (en) 2000-12-22 2004-09-21 Streck Laboratories Inc. Flow cytometry reagent and system
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US7479630B2 (en) 2004-03-25 2009-01-20 Bandura Dmitry R Method and apparatus for flow cytometry linked with elemental analysis
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4532409B2 (ja) 2003-01-23 2010-08-25 小野薬品工業株式会社 ヒトｐｄ−１に対し特異性を有する物質
US7507548B2 (en) 2003-03-04 2009-03-24 University Of Salamanca Multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry measurements
US7354773B2 (en) 2003-05-14 2008-04-08 Beckman Coulter, Inc. Method and apparatus for preparing cell samples for intracellular antigen detection using flow cytometry
WO2005091893A2 (en) 2004-03-03 2005-10-06 Dakocytomation Denmark A/S System for high dynamic range analysis in flow cytometry
US7465543B1 (en) 2004-05-21 2008-12-16 The United States Of America, As Represented By The Secretary Of Agriculture Multiplex DNA identification of clinical yeasts using flow cytometry
US7527978B2 (en) 2004-10-07 2009-05-05 Children's Hospital & Research Center At Oakland Flow cytometry based micronucleus assays and kits
WO2006044717A2 (en) 2004-10-15 2006-04-27 Verisign, Inc. One time password
WO2006056875A1 (en) * 2004-11-29 2006-06-01 Pharmacia & Upjohn Company Llc Thiazepine oxazolidinones as antibacterial agents
US7491502B2 (en) 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
EP2439273B1 (en) * 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Institute métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
WO2008042718A2 (en) 2006-09-29 2008-04-10 Guava Technologies, Inc. Differentiation of flow cytometry pulses and applications
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
CN101236150B (zh) 2007-02-02 2012-09-05 深圳迈瑞生物医疗电子股份有限公司 用于基于流式细胞术的仪器的光电传感器及其照射单元
US7746466B2 (en) 2007-05-14 2010-06-29 The Regents Of The University Of California System and method for flow cytometry
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
ES2639857T3 (es) * 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010029434A1 (en) * 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009290544B2 (en) * 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
JP6087503B2 (ja) * 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
ES2629337T3 (es) * 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies

Also Published As

Publication number Publication date
AU2012245477B2 (en) 2017-03-23
US20140044738A1 (en) 2014-02-13
EP2699264A4 (en) 2014-10-08
SI2699264T1 (en) 2018-08-31
RU2625034C2 (ru) 2017-07-11
DK2699264T3 (en) 2018-06-25
CY1120626T1 (el) 2019-12-11
JP2017101042A (ja) 2017-06-08
JP6072771B2 (ja) 2017-02-01
KR20140048121A (ko) 2014-04-23
CA2833636A1 (en) 2012-10-26
HUE037651T2 (hu) 2018-09-28
US9205148B2 (en) 2015-12-08
MX338353B (es) 2016-04-13
HRP20180893T1 (hr) 2018-07-27
EP2699264A1 (en) 2014-02-26
AU2012245477C1 (en) 2017-06-15
ES2669310T3 (es) 2018-05-24
EP3403672A1 (en) 2018-11-21
KR101970025B1 (ko) 2019-04-17
AU2012245477A1 (en) 2013-10-31
WO2012145493A1 (en) 2012-10-26
RU2013151455A (ru) 2015-05-27
CN103608040A (zh) 2014-02-26
SMT201800294T1 (it) 2018-07-17
EP2699264B1 (en) 2018-03-14
PT2699264T (pt) 2018-05-23
PL2699264T3 (pl) 2018-08-31
LT2699264T (lt) 2018-07-10
RS57324B1 (sr) 2018-08-31
US20160130348A1 (en) 2016-05-12
JP2014523401A (ja) 2014-09-11
CN103608040B (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
MX2013012088A (es) Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
CY1125652T1 (el) Αντι-pdi αντισωματα και η χρηση τους ως θεραπευτικοι και διαγνωστικοι παραγοντες
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
CL2018000422A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
AR088171A1 (es) Anticuerpos anti-erbb3 y usos de los mismos
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
MX2016009444A (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
MX2018014102A (es) Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer.
MX2015008117A (es) Anticuerpos anti-h7cr.
MX2015007846A (es) Anticuerpos anti-b7-h4 humana y sus usos.
UY33850A (es) Anticuerpos anti ? cd38
AR089528A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
UY35042A (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
MX2011010707A (es) Anticuerpos dkk-1.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: MEDIMMUNE, LLC